HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chun, E. Articles by Lee, K.-Y. Search for Related Content PubMed PubMed Citation Articles by Chun, E. Articles by Lee, K.-Y.

Tumor Eradication by Hepatitis B Virus X Antigen-Specific CD8⁺ T Cells in Xenografted Nude Mice

Division of Virology and Immunology, Mogam Biotech. Institute, Koosung-myun, Yongin-city Kyonggi-do, South Korea

We have previously reported several CTL epitopes derived from the hepatitis B viral X Ag (HBx). In this study, we evaluated whether HBx-specific CTLs can be effectively used in adoptive cancer immunotherapy. To validate the possibility, four peptides containing a HLA-A2.1-restricted binding consensus motif were identified from the HBx protein and tested for their ability to activate CTL from PBMCs isolated from chronic carriers of HBV (n = 12). We selected two highly potent epitopes, HBx 52–60 (HLSLRGLFV) and HBx 115–123 (CLFKDWEEL), that are capable of inducing Ag-specific cytotoxic T cells in patient PBMCs. For adoptive immunotherapy using HBx-specific CTLs, we generated CTL clones restricted to the HBx 52–60 or HBx 115–123 peptide using a limiting dilution technique. LC-46, an HBx 52–60-specific clone, is CD62L^-CD69⁺CD45RO⁺CD45RA^-CD25^dim and is stained by IFN- (92%), IL-2 (30%), and TNF- (56%), but not by IL-5, IL-10, IL-12, or TNF-, indicating that the cells are fully activated T cytotoxic 1-type cells. When LC-46 cells were adoptively transferred into xenografted nude mice bearing human hepatomas expressing HLA-A2.1 molecules and intracellular HBx proteins, the tumors were eradicated. Taken together, our data provide solid evidence for the feasibility of adoptive immunotherapy with HBx-sensitized CTLs in hepatitis disease, including hepatocellular carcinoma (HCC).

This article has been cited by other articles:

				M. Kim, H.-B. Moon, K. Kim, and K.-Y. Lee Antigen dose governs the shaping of CTL repertoires in vitro and in vivo Int. Immunol., March 1, 2006; 18(3): 435 - 444. [Abstract] [Full Text] [PDF]

				J. Bae, J. A. Martinson, and H. G. Klingemann Identification of CD19 and CD20 Peptides for Induction of Antigen-Specific CTLs against B-Cell Malignancies Clin. Cancer Res., February 15, 2005; 11(4): 1629 - 1638. [Abstract] [Full Text] [PDF]